Management of patients with chronic hepatitis b before and after liver transplantation: An update

Research output: Contribution to journalArticle

Abstract

The use of newer and more potent antiviral agents against hepatitis B virus (HBV) results in greater viral suppression; however, liver transplantation is still required for complications of HBV infection. Post-transplant outcomes for HBV-related disorders are currently comparable to or slightly better than for other indications for liver transplantation in adults in the United States. In the absence of prophylactic antiviral therapy, recurrent HBV infection occurs invariably in patients with detectable serum HBV-deoxyribonucleic acid (DNA) at the time of transplantation, leading to poorer outcomes with severe graft injury, reduced patient and allograft survival. Therefore, anti-HBV therapy is indicated in all patients with detectable serum HBV-DNA pre-transplantation and prophylactic therapy to prevent recurrent HBV infection is standard-of-care. This review summarizes available evidence for the use of different antiviral agents before liver transplantation, the effectiveness of prophylactic agents in preventing recurrent HBV infection post-liver transplantation, and the efficacy of several regimens for treating recurrent HBV infection post-liver transplantation.

Original languageEnglish
Pages (from-to)102-110
Number of pages9
JournalCurrent Hepatitis Reports
Volume11
Issue number2
DOIs
StatePublished - Jun 1 2012

Fingerprint

Chronic Hepatitis
Hepatitis B virus
Liver Transplantation
Virus Diseases
Antiviral Agents
Transplantation
Transplants
DNA
Standard of Care
Serum
Allografts
Therapeutics
Wounds and Injuries

Keywords

  • Cirrhosis
  • Hepatitis B
  • Liver transplantation

ASJC Scopus subject areas

  • Hepatology
  • Virology

Cite this

Management of patients with chronic hepatitis b before and after liver transplantation : An update. / Carrion, Andres F.; Martin, Paul; O'Brien, Christopher B.

In: Current Hepatitis Reports, Vol. 11, No. 2, 01.06.2012, p. 102-110.

Research output: Contribution to journalArticle

@article{2991bf5b4c9c48eca39ac3222615219c,
title = "Management of patients with chronic hepatitis b before and after liver transplantation: An update",
abstract = "The use of newer and more potent antiviral agents against hepatitis B virus (HBV) results in greater viral suppression; however, liver transplantation is still required for complications of HBV infection. Post-transplant outcomes for HBV-related disorders are currently comparable to or slightly better than for other indications for liver transplantation in adults in the United States. In the absence of prophylactic antiviral therapy, recurrent HBV infection occurs invariably in patients with detectable serum HBV-deoxyribonucleic acid (DNA) at the time of transplantation, leading to poorer outcomes with severe graft injury, reduced patient and allograft survival. Therefore, anti-HBV therapy is indicated in all patients with detectable serum HBV-DNA pre-transplantation and prophylactic therapy to prevent recurrent HBV infection is standard-of-care. This review summarizes available evidence for the use of different antiviral agents before liver transplantation, the effectiveness of prophylactic agents in preventing recurrent HBV infection post-liver transplantation, and the efficacy of several regimens for treating recurrent HBV infection post-liver transplantation.",
keywords = "Cirrhosis, Hepatitis B, Liver transplantation",
author = "Carrion, {Andres F.} and Paul Martin and O'Brien, {Christopher B}",
year = "2012",
month = "6",
day = "1",
doi = "10.1007/s11901-012-0128-4",
language = "English",
volume = "11",
pages = "102--110",
journal = "Current Hepatitis Reports",
issn = "1540-3416",
publisher = "Springer Publishing Company",
number = "2",

}

TY - JOUR

T1 - Management of patients with chronic hepatitis b before and after liver transplantation

T2 - An update

AU - Carrion, Andres F.

AU - Martin, Paul

AU - O'Brien, Christopher B

PY - 2012/6/1

Y1 - 2012/6/1

N2 - The use of newer and more potent antiviral agents against hepatitis B virus (HBV) results in greater viral suppression; however, liver transplantation is still required for complications of HBV infection. Post-transplant outcomes for HBV-related disorders are currently comparable to or slightly better than for other indications for liver transplantation in adults in the United States. In the absence of prophylactic antiviral therapy, recurrent HBV infection occurs invariably in patients with detectable serum HBV-deoxyribonucleic acid (DNA) at the time of transplantation, leading to poorer outcomes with severe graft injury, reduced patient and allograft survival. Therefore, anti-HBV therapy is indicated in all patients with detectable serum HBV-DNA pre-transplantation and prophylactic therapy to prevent recurrent HBV infection is standard-of-care. This review summarizes available evidence for the use of different antiviral agents before liver transplantation, the effectiveness of prophylactic agents in preventing recurrent HBV infection post-liver transplantation, and the efficacy of several regimens for treating recurrent HBV infection post-liver transplantation.

AB - The use of newer and more potent antiviral agents against hepatitis B virus (HBV) results in greater viral suppression; however, liver transplantation is still required for complications of HBV infection. Post-transplant outcomes for HBV-related disorders are currently comparable to or slightly better than for other indications for liver transplantation in adults in the United States. In the absence of prophylactic antiviral therapy, recurrent HBV infection occurs invariably in patients with detectable serum HBV-deoxyribonucleic acid (DNA) at the time of transplantation, leading to poorer outcomes with severe graft injury, reduced patient and allograft survival. Therefore, anti-HBV therapy is indicated in all patients with detectable serum HBV-DNA pre-transplantation and prophylactic therapy to prevent recurrent HBV infection is standard-of-care. This review summarizes available evidence for the use of different antiviral agents before liver transplantation, the effectiveness of prophylactic agents in preventing recurrent HBV infection post-liver transplantation, and the efficacy of several regimens for treating recurrent HBV infection post-liver transplantation.

KW - Cirrhosis

KW - Hepatitis B

KW - Liver transplantation

UR - http://www.scopus.com/inward/record.url?scp=84865724066&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865724066&partnerID=8YFLogxK

U2 - 10.1007/s11901-012-0128-4

DO - 10.1007/s11901-012-0128-4

M3 - Article

AN - SCOPUS:84865724066

VL - 11

SP - 102

EP - 110

JO - Current Hepatitis Reports

JF - Current Hepatitis Reports

SN - 1540-3416

IS - 2

ER -